Protein Design Labs

Executive Summary

MSL-109 Phase I/II trial results indicate the anti-cytomegalovirus antibody in combination with ganciclovir or foscarnet may delay progression to CMV retinitis at least twice as long as either drug alone. The data on 17 AIDS patients, presented June 10 at the Ninth International Conference on AIDS in Berlin, show that median delay in progression to CMV retinitis was 202 days compared to 60-100 days for ganciclovir or foscarnet in other studies. Protein Design Labs is planning to begin a Phase II/III trial of MSL-109 in CMV retinitis next year.